Research Analysts Offer Predictions for RADX Q3 Earnings

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) – Analysts at Zacks Research issued their Q3 2026 earnings per share estimates for shares of Radiopharm Theranostics in a research report issued on Tuesday, May 12th. Zacks Research analyst J. Vandermosten expects that the company will earn $0.00 per share for the quarter. The consensus estimate for Radiopharm Theranostics’ current full-year earnings is ($2.70) per share. Zacks Research also issued estimates for Radiopharm Theranostics’ Q4 2026 earnings at ($0.01) EPS.

Other research analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Tuesday, April 21st. Wall Street Zen cut Radiopharm Theranostics to a “strong sell” rating in a research report on Friday, January 23rd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $16.00.

Radiopharm Theranostics Stock Up 8.7%

NASDAQ:RADX opened at $4.52 on Thursday. The stock has a 50-day simple moving average of $4.54 and a 200-day simple moving average of $4.83. Radiopharm Theranostics has a 1 year low of $3.62 and a 1 year high of $16.25.

Radiopharm Theranostics (NASDAQ:RADX) last issued its quarterly earnings results on Wednesday, January 28th. The company reported ($1.58) earnings per share for the quarter. The business had revenue of $0.46 million during the quarter.

Institutional Trading of Radiopharm Theranostics

A number of large investors have recently made changes to their positions in the company. Hsbc Holdings PLC acquired a new stake in shares of Radiopharm Theranostics in the 4th quarter valued at about $1,007,000. PNC Financial Services Group Inc. boosted its position in shares of Radiopharm Theranostics by 100.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company’s stock valued at $88,000 after purchasing an additional 8,000 shares during the period. Virtu Financial LLC acquired a new stake in shares of Radiopharm Theranostics in the 4th quarter valued at about $76,000. Jane Street Group LLC acquired a new stake in shares of Radiopharm Theranostics in the 4th quarter valued at about $76,000. Finally, Marex Group plc acquired a new stake in shares of Radiopharm Theranostics in the 4th quarter valued at about $54,000.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.